Genoskin has announced it has raised $8.7m in its first venture capital funding round.
The Contract Research Organisation (CRO), which was the first to develop ex vivo human skin platforms capable of testing injected drugs and implanted medical devices, will use the financing to accelerate international expansion.
Genoskin’s models also generate large-scale datasets through multiomics approaches, which are further analysed using AI and advanced bioinformatics to deliver meaningful insights into the toxicity and efficacy of tested products in humans.
The financing will drive Genoskin’s next phase of growth and support further staff recruitment, with a view to doubling the size of the company within the next three years and expanding Genoskin’s commercial presence in key global markets.
Genoskin plans to launch new immune-centric service offerings by 2027 and strengthen its scientific and regulatory leadership with the development of biosimulation platforms and novel human immune models to reduce reliance on animal testing.
Genoskin will also scale up operations through increased production capacity in both the US and France by moving into two updated and expanded facilities, one in Salem (700sqm) in 2026 and the other in Toulouse (1000sqm) in 2027.
This will double the production of skin models and launch the production of fresh human primary mast cells for next-day delivery in the US.
“This funding gives Genoskin the resources to scale globally, strengthen our presence in key markets and accelerate the development of our innovative platforms."
"As a company built on ethical innovation, we are proud to offer sustainable, human-relevant alternatives to animal testing."
"This investment validates our strategy and reinforces our position as a leader in predictive immunotoxicology using live human skin models,” said Pascal Descargues, CEO of Genoskin.
“With the support of our investors, Genoskin is well-positioned to drive meaningful change in how biotherapies are developed, ultimately bringing safer treatments to patients worldwide.”
Demand for alternative testing models is projected to grow from $108.6bn in 2025 to $155.4bn by 2034 at a CAGR of 4.1%.
At the same time, biotechnology and pharmaceutical companies face mounting international pressure from regulatory bodies to reduce or eliminate animal testing, creating demand for ethical alternatives.
By leveraging donated human skin and its own proprietary preservation technology, Genoskin provides live immunocompetent ex vivo platforms that remain viable for up to seven days post-surgery, enabling more human-relevant testing than traditional animal or engineered models.
Julien Gomis, managing partner at OCCTE, said: “We are proud to support Genoskin, a company that perfectly embodies our mission to invest in local innovators delivering sustainable solutions with global reach."
"Genoskin’s technology offers an ethical, scalable alternative to animal testing and pursues a growth strategy that aligns strongly with our values of economic resilience and scientific impact."
“Captech Santé is pleased to contribute to the financing of Genoskin, a company capable of setting new global standards in the development of injectable drugs and that already counts most major global pharmaceutical companies amongst its clients,” added Alexandre Demailly, investor at Captech Santé.